Drugs / IMT-002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04625595 | Nov 2020 → May 2021 | type 1 diabetes mellitus | Immunomolecular Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMT-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04625595 ↗ |
| Known as | D-methyldopa | “350mg BID (700mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule” NCT04625595 ↗ |
| Route | Oral | “Oral drug or placebo self-administered by subject as a capsule by mouth once-daily or twice-daily” NCT04625595 ↗ |